INTRODUCTION
Accepted: September 2, 1999 Whatever types of gonadotrophins are used for ovarian collection for in vitro fertilization.
Methods: Twenty patients experienced within a period of
The hMG and FSH preparations contain similar four months both preparations in subsequent cycles through amounts of FSH and LH only in the first preparation.
a prospective randomized cross-over design. A standard hormonal treatment consisting of a flare-up protocol using
Consequently, the value of exogenous LH administered gonadotrophin-releasing hormone agonist (GnRHa) col has been advocated for such patients (8) . As maternal gamete characteristics are clearly affected by KEY WORDS: cross-over; FSH; hMG; IVF.
advancing age (9, 10) , exogenous administration of LH during ovarian stimulation with a short protocol using hMG might be deleterious on such gametes in these patients. Highly purified follicle-stimulating hormone (H.P. FSH) derived from human urine is now available 1 Centre hospitalier de Luxembourg, Department of Obstetrics and for ovarian hyperstimulation before IVF and has been Gynecology, L-1210 Luxembourg, Grand Duchy of Luxembourg. used in randomized comparative studies (11) . Its spe- 2 Catholic University of Louvain, Faculty of Medicine, Department cific bioactivity is much higher compared to the classiof Gynecology and Andrology, St. Luc's University Hospital, Brussels, Belgium.
cally available urinary gonadotrophins (12) . The H.P. 3 To whom correspondence should be addressed at Centre hospi-FSH preparation has no LH activity and its use during istration used with hMG preparations.
The aim of this study was to compare the ovarian Geneva, Switzerland) or hMG (Pergonal, Serono, Geneva, Switzerland) were compared during ovarian response using GnRHa/H.P. FSH and GnRHa/hMG stimulation regimens in the same women. Through a stimulation for IVF in women aged 37-41 years. After they had given their informed consent, patients starting prospective, randomized, cross-over study, 20 patients aged between 37 and 41 years experienced, in subsetheir first IVF attempt were allocated randomly to either GnRHa/hMG or GnRHa/FSH treatment. In the quent cycles, the one and the other treatment for ovarian hyperstimulation before IVF. As the effect of aging absence of pregnancy, the patients were allocated to the other arm of treatment for a subsequent cycle. on LH levels has been linked to poor gamete quality, we choose this group of patients in order to evaluate if they could benefit from the highly purified FSH Hormonal Treatment preparation. From this point of view, the cross-over A short version of combined GnRHa therapy was design was the most accurate way to determine how used. Women began GnRHa on the first day of the each gonadotrophin preparation would act on the same cycle in the form of Buserelin nasal spray, 900 g/ patient. Our main end-points were the comparison of 24 h (Suprefactா, Hoechst, Brussels, Belgium) and the results of stimulation parameters (i.e., day of hCG continued this treatment up to the day of hCG adminisadministration, the total dose of gonadotrophin used, tration. On the third day of the cycle, administration the E 2 levels on the day of hCG administration, the of 300 IU of gonadotrophins (hMG or FSH according LH levels before and after gonadotrophin administrato randomization) was commenced for 3 days. The tion, the total number of oocytes retrieved) and embryo hMG preparation was administered intramuscularly quality for each regimen of treatment.
and the H.P. FSH preparation subcutaneously as recommended by the manufacturer. Vaginal ultrasound with serum estradiol level measurement was initiated MATERIALS AND METHODS from the sixth day, and gonadotrophin doses were adapted according to the ovarian response. Human Twenty-seven patients undergoing their first IVF chorionic gonadotrophin was administered (10,000 cycle were randomized for this trial. The Ethical Com-IU)(Profasiா, Serono, Geneva, Switzerland) in the mittee of St. Luc's University Hospital approved the presence of more than 2 follicles over 18 mm in diamestudy.
ter with an estradiol level of 150 pg/ml per follicle over Inclusion criteria were patients aged between 37 and 15 mm in diameter. The criteria for hCG administration 41 years, normal cycles Day 3 FSH levels defined in were the same in both treatment groups. our Laboratory as 8 mlU/ml, the presence of both ovaries, a body mass index between 18 and 28, and a Ovocyte Retrieval, In Vitro Culture, and cycle length between 26-32 days. The cut-off FSH Embryo Evaluation value of 8 mlU/ml was established to have a homogeneous group in order to avoid poor responders in this Thirty-five hr after hCG injection, oocytes were age group.
retrieved by transvaginal ultrasound guidance. AspiOnly 20 patients subsequently completed the two rated oocytes were cultured in IVF medium (Medicult, regimens of treatment within a period of four months.
Copenhagen, Denmark) in air containing 5% CO 2 and Three patients were excluded because of the occur-100% humidity. Oocytes were inseminated 3 hr after rence of pregnancy during the first cycle, and they retrieval either by adding 100,000 spermatozoa to the were unable to enter the cross-over arm. Two patients culture medium or by ICSI if indicated. Each oocyte (one in each treatment group) ended without ovocyte was checked for fertilization 18 hr after insemination retrieval because of the absence of ovarian response and then transferred to fresh IVF medium. Forty-eight to gonadotrophin therapy. Two patients were excluded hr after retrieval, the developmental stage of the because they did not wish to participate in the study embryo was checked under an inverted microscope in their subsequent cycles.
and scored according to the classification previously reported (13) .
Study Design
Embryo Transfer and Luteal Phase Support This was a prospective, randomized, cross-over study. Two protocols of treatment using GnRHa with After embryo evaluation, patients were given the choice between 2 or 3 embryos for transfer. The transeither highly purified FSH (Metrodin HPா, Serono, fer was performed in the gynecological position using Cycles stimulated with H.P. FSH showed a significantly (P ϭ 0.01) shorter length of stimulation (13 a Frydman catheter (CCD, Paris, France). Each patient was given luteal support in the form of 30 mg of days) than cycles treated with hMG. The mean number of oocytes retrieved per cycle was 10.3 Ϯ 3 and 7.3 dyhydrogesterone (Duphastonா, Duphar, Brussels, Belgium) daily.
Ϯ 5 for the first and second groups respectively. This difference was statistically significant (P ϭ 0.02). In group 1, the mean LH level on Day 3 before gonadotroStatistical Analysis phin administration was higher than in the second group. This level remained higher on the sixth day in Statistical analysis was carried out using the paired the same group and it reached a significant level (P student t test to calculate the mean and the 2 Fisher Ͻ 0.03). The mean total number of embryos replaced exact test (small number of patients) for percentages.
was similar in the two groups. A P value Ͻ 0.05 was considered significant. The endPatients treated with H.P. FSH presented with a points of the study were the comparison of stimulation higher total number of embryos and a higher number parameters, the total dose of gonadotrophins adminisof good quality embryos available for transfer. The tered, the number of oocytes recovered, the fertilization results are detailed in Table II . In the first group, 73.6% rate observed, and the quality of embryos obtained.
of embryos available were of excellent or good quality, compared to 58% in the second group. Out of 34 embryos replaced in group 1, 8 implanted RESULTS compared to 3 out of the 34 placed in group 2. This represents an implantation rate of 23.5% for patients Twenty-seven patients were randomized for this treated with H.P. FSH compared to 9% for those treated trial. The analysis represents data from 20 patients with hMG. However, this difference was not statistiwho completed either the first or the second regimen cally significant (P ϭ 0.09). of treatment. Indeed, seven patients were excluded
In the first and second groups, 13 cycles ended in either because of the occurrence of pregnancy during embryo transfer. The clinical pregnancy rates according the first cycle (N ϭ 3) , or the absence of ovarian to each group are listed in Table 3 . In 65% of cycles, response (N ϭ 2) or drop-out from the study between an embryo transfer was possible in each group; however, the first and second cycles (N ϭ 2). The first group in the group treated with H.P. FSH, 57 embryos were was allocated to purified urinary FSH treatment (group available for transfer compared to only 43 in the group 1: GnRHa/Metrodin HP treatment) and the second treated with hMG. The pregnancy rate/ET was respecgroup to hMG treatment (group 2: GnRHa/hMG treattively 46% and 15% in the first and the second groups ment). Forty cycles were included in the statistical and the pregnancy rate per cycle was respectively 30% analysis. The overall clinical pregnancy rate was 20%/ and 10%. This difference, though statistically significycle (8 pregnancies/40 cycles) and 40%/patient (8/ cant, could not be taken into consideration because of 20 patients, respectively).
the cross-over study design. Pregnancies obtained durThe mean age of the patients was 37.6 Ϯ 2.5 years ing first cycles need to be added. This gives a total (range: 37-41). The stimulation parameters and IVF outcome results are listed in Table I. number of 21 cycles in the H.P. FSH group with 14 transfers and 22 cycles in the hMG group with 15 days) and a higher mean number of oocytes recovered (10.3 Ϯ 5) after puncture compared to cycles treated transfers. Thus, the clinical pregnancy rates were 7 out of 14 transfers (50%) and 7 out of 21 cycles (33.3%) with hMG. The mean total dose of FSH administered per cycle was lower in the first group (3.067 IU) than in the first group, compared to 4 out of 15 transfers (26%) and 4 out of 22 cycles (18%) in the second group.
the total dose of hMG used in the second group (3.750 IU). These results are in accordance with the results These differences were not statistically significant.
of parallel randomized studies on patients treated with H.P. FSH/hMG after down regulation (2, 17, 18, 19) . However, in our study, the difference did not reach DISCUSSION significant levels. This could be a result of the small number of cycles. The fertilization rates per oocyte Many investigators have compared FSH and hMG and concluded that no differences exist (14, 15, 16) .
retrieved were similar in the two groups and nontransferred cycles with failures of fertilization were mainly Recently, Daya et al. (17) reported that previous conclusions may have been premature and suggested, associated with male factors and were not associated with high LH levels. Several studies have demonthrough their meta-analysis of randomized studies, that FSH is associated with a higher clinical pregnancy strated that high LH concentrations predispose patients to lower fertilization rates (1, 7, 20, 21) . It has been sugrate. The present study is different from previous ones because each patient experienced both gonadotrophin gested that higher LH concentrations may prematurely allow resumption of meiotic maturation (22) inducing treatments at the same dose and within an interval of 4 months. Also, in order to determine whether there a recovery of postmature oocytes that would probably fail to fertilize. This effect was not observed in our is any benefit from the use of purified FSH, we selected patients aged 37-41 years with normal FSH levels on study. The LH serum levels on Day 3 and Day 6 of the cycle were determined during each treatment in cycle Day 3.
The use of highly purified urinary FSH was associthe same woman. As shown in Table I , LH concentrations were similar on Day 3 but, surprisingly, they ated with a significantly shorter stimulation length (13 compared to cycles treated with hMG may explain the higher number of embryos of good quality obtained in group 1 had a higher mean concentration of LH before gonadotrophin administration. Also, the differin the H.P. FSH-treated group, giving the possibility of transferring better embryos which may lead to a ence observed between the two groups in mean LH concentrations on Day 6 (⌬LH Day 6 ϭ 1 Ϯ 0.05) higher pregnancy rate. Staessen et al. (24) and, later, our group (13) demonstrated that the number of was similar to the difference observed on Day 3 (⌬LH Day 3 ϭ 1 Ϯ 0.01). In addition, the significantly higher embryos transferred correlated better with the pregnancy rate when it was possible to make the selection mean LH concentrations found in H.P. FSH-treated patients may suggest that exogenous LH in hMG prepfrom a larger cohort of embryos available for placement (13). arations is not detected in blood circulation with our dosage technique or that these LH amounts were not
In our study, patients between 37 and 41 years of age ended with a higher number of available oocytes sufficient to influence endogenous secretion and so were not detected in blood circulation. Also, the endogand embryos of good quality in cycles treated with H.P. FSH compared to cycles treated with hMG. This enous pulses of LH vary considerably and contribute to the total amount of LH present during follicular is associated with a better prognosis for IVF outcome. Taking into consideration only patients who completed development. This endogenous effect may explain why the same patients had a different LH level in each the two regimens of treatment, this improved prognosis was reflected in the higher pregnancy rate obtained in cycle and reflect an intercycle variation (23) . In a recent report, Westergaard et al. (16) did not find any H.P. FSH-treated cycles. However, for accurate statistical analysis, we added the pregnancies obtained during detrimental effect of the LH activity of hMG on the clinical outcome of IVF in GnRHa down-regulated the first cycle in each group, and these data were analyzed as in a parallel randomized study. Using this women. Even if an LH effect could not be ruled out in our study because patients were not down-regulated, method, the pregnancy rates obtained were not statistically significant in the two groups. the similar number of embryos obtained per ovocyte inseminated strongly suggests the absence of such a One might consider the cross-over study design as a factor of overestimation for one or the other treatment detrimental effect. This was also demonstrated in the study by Westergaard et al. (16) and Fleming et al. (25) . In our study, this could be ruled out as pregnancy outcome was not the main point of comparison. The (21) . On the other hand, in a randomized, prospective study, Daya et al. (2, 17) compared the effects of FSH end-points of the study were to compare the parameters that could be directly affected by such treatment, such (Metrodin) and hMG in IVF and found, in contrast to the present results, a statistically higher fertilization as the duration of stimulation, the number of ovocytes recovered, and the embryo quality in relation to LH rate in patients treated with FSH compared to hMG. They concluded that the LH activity of hMG accounted activity. Indeed, Te Velde and Looman (26) recently ruled out the claims made by Khan et al. (25) and for the proper results in the hMG group compared to the FSH group. This is at odds with our results, and concluded in favor of a cross-over design for infertility studies. One of the limitations of our study may be we believe that the small amount of LH present in hMG preparations may not influence the fertilization the number of cycles included and further investigations may be necessary to confirm our results. Howprocess.
The beneficial effect of FSH over hMG was only ever, in women aged 37-41 years, with normal basal Day 3 FSH levels, normal ovulation, and a BMI Ͻ28 visible on the duration of stimulation and on follicular recruitment. The explanation of such an effect, in theundergoing IVF treatment, the use of H.P. FSH for ovarian stimulation may be the best choice to induce ory at least, may be related to the injection site and biological properties of the H.P. FSH preparation. The a good ovarian response. FSH isoforms in Metrodin HP are more acidic than other urinary gonadotrophin preparations (20) . Acidic REFERENCES isoforms have a longer half-life than basic FSH isoforms. It might be expected that such acidic forms 
